How often esophageal cancer spreads to the subcarinal (107) lymph node
Official title: A Prospective Observational Study of Subcarinal Lymph Node Metastasis in Patients With Esophageal Cancer
Run by Fudan University · NCT07165184 · Data updated 2026-11-12
This study will try to find how often esophageal squamous cell carcinoma spreads to the subcarinal (107) lymph node and which patients are more likely to have that spread when they undergo esophagectomy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 85 Years |
| Sex | All |
| Enrollment | 1100 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | July 21, 2025 |
| Main results expected | July 21, 2027 |
| Study ends | July 21, 2030 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT07165184 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with esophageal squamous cell carcinoma staged cT1-4a N0/+ M0 who are medically fit for esophagectomy and have no history of other malignancies.
✕Probably not a fit
Patients with cervical (neck) esophageal cancer, non-squamous histology, distant metastases, or who are too frail for surgery are unlikely to benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational study at Fudan University Shanghai Cancer Center enrolling patients with esophageal squamous cell carcinoma (cT1-4a N0/+ M0) who are planned for esophagectomy. Surgeons will document whether subcarinal (station 107) lymph nodes contain cancer and collect clinical and pathological data to identify risk factors for metastasis. The study aims to quantify the incidence of subcarinal metastasis and examine its relation to postoperative respiratory complications and long-term outcomes. The goal is to provide evidence to guide whether routine removal of subcarinal nodes is necessary given potential harms from dissection.
Why it matters
Potential benefit: If successful, the results could help surgeons avoid unnecessary subcarinal node removal, reducing postoperative respiratory complications while maintaining cancer control.
How similar studies have gone: Retrospective data have reported a low (~2%) rate of subcarinal metastasis and mixed results on the benefit of extended nodal dissection, while prospective confirmation is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with esophageal squamous cell carcinoma * clinical staging: cT1-4a N0/+ M0. * no history of other malignancy. Exclusion Criteria: * esophageal cancer in the neck * poor physical status to have esophagectomy.
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Bin Li, MD
- Email: lb0256327@hotmail.com
- Phone: 086-021-64175590-82500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.